12/01 | Surrozen: Targeted Regeneration Presentation |  |
05/01 | Surrozen, Inc./de: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or .. |  |
04/01 | Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference |  |
2022 | Top Premarket Decliners |  |
2022 | Surrozen, Inc./de: Other Events (form 8-K) |  |
2022 | Surrozen: Repurchase of Common Stock and Warrants to Purchase Common Stock - Form 8-K |  |
2022 | Weaker-Than-Expected Retail Sales, Hawkish Fed Send US Stock Futures Sharply Lower |  |
2022 | Tranche Update on Surrozen, Inc.'s Equity Buyback Plan announced on December 15, 2022. |  |
2022 | Surrozen, Inc. announces an Equity Buyback for 1,310,496 shares, for $2.7 million. |  |
2022 | Federal Reserve's Still-Hawkish Stance Appears to Disappoint Investors; US Futures Move.. |  |
2022 | Top Premarket Gainers |  |
2022 | Surrozen, Inc.'s Equity Buyback announced on December 15, 2022, has closed with 1,310,4.. |  |
2022 | Surrozen Files $200 Million Mixed Shelf |  |
2022 | Surrozen, Inc. authorizes a Buyback Plan. |  |
2022 | Surrozen, Inc. Updates SZN-1326, SZN-043 and SZN-413 for Vascular-Associated Retinopath.. |  |
2022 | SURROZEN, INC./DE Management's Discussion and Analysis of Financial Condition and Resu.. |  |
2022 | Surrozen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended Sep.. |  |
2022 | Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update |  |
2022 | Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroente.. |  |
2022 | Surrozen, Boehringer Ingelheim to Support Research, Development of Retinal Diseases Tre.. |  |
2022 | Surrozen, Inc./de: Entry into a Material Definitive Agreement (form 8-K) |  |
2022 | Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agoni.. |  |
2022 | Surrozen, Inc. Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt.. |  |
2022 | Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating t.. |  |
2022 | Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating t.. |  |
2022 | Surrozen: SZN-1326 13-week GLP Toxicity Studies |  |
2022 | Surrozen: SZN-043 Hepatocyte Proliferation in 14-day daily dosing Edu-labeling study |  |
2022 | SURROZEN, INC./DE Management's Discussion and Analysis of Financial Condition and Resu.. |  |
2022 | Surrozen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended Jun.. |  |
2022 | Surrozen: Reports Second Quarter 2022 Financial Results - Form 8-K |  |
2022 | Surrozen Reports Second Quarter 2022 Financial Results |  |
2022 | Surrozen, Inc.(NasdaqCM:SRZN) added to Russell Microcap Value In.. |  |
2022 | Surrozen, Inc.(NasdaqCM:SRZN) added to Russell 3000E Index |  |
2022 | Surrozen, Inc.(NasdaqCM:SRZN) added to Russell Microcap Index |  |
2022 | Surrozen, Inc.(NasdaqCM:SRZN) added to Russell 3000E Value Index |  |
2022 | Surrozen, Inc./de: Submission of Matters to a Vote of Security Holders, Financial Stateme.. |  |
2022 | Surrozen Doses First Patient in Early Trial of SZN-043 to Treat Alcoholic Hepatitis |  |
2022 | Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hep.. |  |
2022 | Surrozen, Inc. Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcohol.. |  |
2022 | Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW) |  |
2022 | Surrozen, Inc. Presents Data on Lead Therapeutic Candidates at Digestive Disease Week |  |
2022 | Surrozen Begins Dosing in Phase 1 Study of Ulcerative Colitis Treatment; Shares Rise Ea.. |  |
2022 | Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe .. |  |
2022 | Surrozen, Inc. Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to S.. |  |
2022 | Surrozen: SZN-043 Induced Quick and Robust Hepatocyte Proliferation in a 14-Day Daily Dos.. |  |
2022 | Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology De.. |  |
2022 | SURROZEN, INC./DE Management's Discussion and Analysis of Financial Condition and Resu.. |  |
2022 | Surrozen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 |  |
2022 | Surrozen Reports First Quarter 2022 Financial Results |  |
2022 | Surrozen to Present at the BofA Securities 2022 Healthcare Conference |  |
2022 | Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Re.. |  |
2022 | Surrozen, Inc. Presents Data Supporting Potential of SZN-413 for the Treatment of Diabe.. |  |
2022 | Surrozen: Association for Research in Vision and Ophthalmology |  |
2022 | SURROZEN, INC./DE Management's Discussion and Analysis of Financial Condition and Resu.. |  |
2022 | Surrozen: Reports Fourth Quarter and Full Year 2021 Financial Results - Form 8-K |  |
2022 | Surrozen, Inc./de: Results of Operations and Financial Condition, Shareholder Director No.. |  |
2022 | Surrozen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 |  |
2022 | Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results |  |
2022 | Surrozen, Inc./de: Entry into a Material Definitive Agreement, Unregistered Sale of Equit.. |  |
2022 | Surrozen: Pep Talk 2022 Poster |  |
2022 | Surrozen: Investor Presentation January 2022 |  |
2022 | Surrozen, Inc./de: Other Events (form 8-K) |  |
2022 | Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research P.. |  |
2022 | Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference |  |
2021 | Surrozen: Reports Third Quarter 2021 Financial Results - Form 8-K |  |
2021 | Surrozen Reports Third Quarter 2021 Financial Results |  |
2021 | Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference |  |
2021 | Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference |  |
2021 | Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the A.. |  |
2021 | Surrozen, Inc. Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021,.. |  |
2021 | Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference |  |
2021 | Surrozen : Drug Candidate Shows Potential in Bowel Disease Based on Preclinical.. |  |
2021 | Surrozen: Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gas.. |  |
2021 | Surrozen: Announces Appointment of Liz Nguyen as Vice President and Head of Human Resourc.. |  |
2021 | Surrozen, Inc. Announces Appointment of Liz Nguyen as Vice President and Head of Human .. |  |
2021 | Surrozen, Inc.(NasdaqCM:SRZN) added to S&P TMI Index |  |
2021 | Top Midday Gainers |  |
2021 | Surrozen : Stock Jumps after Stifel Begins Coverage |  |
2021 | Surrozen: Unaudited Condensed Interim Financial Statements for the Three and Six Months E.. |  |
2021 | Consonance-HFW Acquisition Corp.(NasdaqCM:SRZN) add.. |  |
2021 | Consonance Hfw Acquisition: Common stock and warrants to commence trading on Nasdaq on Au.. |  |
2021 | Consonance Hfw Acquisition: Surrozen Debuts as Publicly Traded Leader in Wnt Biology and .. |  |
2021 | Surrozen, Inc. announced that it has received $120.2 million in funding from Consonance.. |  |
2021 | Surrozen, Inc. completed the acquisition of Consonance-HFW Acquisition Corp. from Conso.. |  |
2021 | Consonance-Hfw Acquisition Corp. Reports Earnings Results for the Second Quarter Ended .. |  |
2021 | Consonance Hfw Acquisition: Business Combination Agreement (Form 8-K) |  |
2021 | Consonance Hfw Acquisition: New Surrozen to Trade on Nasdaq as "SRZN" (Form 8-K) |  |
2021 | Consonance Hfw Acquisition: New Surrozen to Trade on Nasdaq as “SRZN” |  |
2021 | Consonance-Hfw Acquisition Corp. Reports Earnings Results for the First Quarter Ended M.. |  |
2021 | Certain Class B Ordinary Shares of Consonance-HFW Acquisition Corp. are subject to a Lo.. |  |
2021 | Surrozen, Inc. Auditor Raises 'Going Concern' Doubt |  |
2021 | Consonance HFW Acquisition : Surrozen Agrees to Merge With SP.. |  |
2021 | Consonance Hfw Acquisition: Surrozen and Consonance-HFW Acquisition Corp. Announce Busine.. |  |
2021 | Surrozen, Inc. announced that it expects to receive $120.2 million in funding from Cons.. |  |
2021 | Surrozen, Inc. signed a definitive agreement to acquire Consonance-HFW Acquisition Corp.. |  |
2020 | Consonance-HFW Acquisition Corp. announced that it has received $4.1 million in funding.. |  |
2020 | Consonance-HFW Acquisition Corp. has completed an IPO in the amount of $80 million. |  |
2020 | Consonance-HFW Acquisition Corp. has filed an IPO in the amount of $100 million. |  |
2020 | Consonance-HFW Acquisition Corp. announced that it expects to receive $4.5 million in f.. |  |
2016 | Surrozen, Inc. announced that it expects to receive $33.555555 million in funding |  |